In summary, we demonstrated here that LicA is a novel BDNF/TrkB inhibitor that suppresses gene transcription selectively; therefore, LicA may potentially be a key therapeutic compound for the treatment of malignant tumors including neuroblastoma and CRC. Here, NTRK2 is linked to cancer.